Stribild elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate regulatory update

Gilead said the European Commission approved an MAA for Stribild to treat HIV-1 infection in treatment-naïve adults or adults without mutations associated with resistance to the antiviral agents in the product. Gilead said it will launch Stribild immediately in the U.K. and Germany. FDA approved the once-daily tablet comprising elvitegravir, cobicistat and Truvada emtricitabine/tenofovir for the treatment-naïve indication last August. The product is also approved in Canada, South Korea, Japan, Turkey and Australia. ...